Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Abbott Laboratories Barclays Buy 52
AbbVie Inc. UBS Buy 78
Aetna Inc. BofA/Merrill Buy 162
Alexion Pharmaceuticals, Inc. UBS Buy 223
Allergan plc Deutsche Bank Buy 342
Amgen Inc. Deutsche Bank Buy 180
Anthem, Inc. RBC Capital Mkts Buy 198
Becton, Dickinson and Company Deutsche Bank Buy 167
Biogen Inc. Bernstein Buy 360
Boston Scientific Corporation Deutsche Bank Buy 22
Bristol-Myers Squibb Company Morgan Stanley Buy 80
Celgene Corporation UBS Buy 156
Cigna Corp. Barclays Buy 156
CVS Health Corporation Deutsche Bank Buy 118
DaVita HealthCare Partners Inc. RBC Capital Mkts Buy 83
DENTSPLY International Inc. Morgan Stanley Buy 70
Edwards Lifesciences Corp. RBC Capital Mkts Buy 160
Eli Lilly and Company BofA/Merrill Buy 90
Endo International plc Deutsche Bank Buy 88
Express Scripts Holding Company RBC Capital Mkts Buy 95
1 2